Durvalumab (D) plus /- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial

被引：7

作者：

Thibault, C. ^{[1
]}

Bennamoun, M. ^{[2
]}

Flechon, A. ^{[3
]}

Gravis, G. ^{[4
]}

Pouessel, D. ^{[5
]}

Combe, P-F. ^{[6
]}

Borchiellini, D. ^{[7
]}

Loriot, Y. ^{[8
]}

Laguerre, B. ^{[9
]}

Barthelemy, P. ^{[10
]}

Goupil, M. Gross ^{[11
]}

Helissey, C. ^{[12
]}

Huillard, O. ^{[13
]}

Cancel, M. ^{[14
]}

Campedel, L. ^{[15
]}

Audenet, F. ^{[16
]}

Belhouari, H. ^{[17
]}

Kotti, S. ^{[17
]}

Tran, Y. ^{[18
]}

Oudard, S. ^{[1
]}

机构：

[1] HEGP, AP HP, Med Oncol Dept, Paris, France

[2] Inst Mutualiste Montsouris, Oncol, Paris, France

[3] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[4] IPC, Dept Med Oncol, Immun & Canc Team, Marseille, France

[5] Oncopole Claudius Regaud Inst Univ Canc, Dept Med Oncol, Toulouse, France

[6] Pole Sante Leonard de Vinci, Oncol, Chambray Les Tours, France

[7] Ctr Anticanc Antoine Lacassagne, Dept Med Oncol, Nice, France

[8] Inst Gustave Roussy, DITEP, Villejuif, France

[9] Ctr Eugene Marquis, Med Oncol, Rennes, France

[10] ICANS Inst Cancerol Strasbourg Europe, Dept Med Oncol, Strasbourg, France

[11] CHU Bordeaux Hop St Andre, Dept Med Oncol, Bordeaux, France

[12] Mil Hosp Begin, Clin Res Unit, St Mande, France

[13] Hop Cochin, AP HP, Cancerol, Paris, France

[14] Univ Hosp Tours, Dept Med Oncol, Tours, France

[15] Hop La Pitie Salpetriere, Dept Med Oncol, Paris, France

[16] HEGP, AP HP, Paris, France

[17] ARTIC, Med Oncol, Paris, France

[18] ARTIC, Stat, Paris, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2364MO

引用

页码：S1202 / S1202

页数：1

共 38 条

[31] CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC). [J].

Chen, Eric Xueyu ;

Jonker, Derek J. ;

Kennecke, Hagen F. ;

Berry, Scott R. ;

Couture, Felix ;

Ahmad, Chaudhary E. ;

Goffin, John R. ;

Kavan, Petr ;

Harb, Mohammed ;

Colwell, Bruce ;

Samimi, Setareh ;

Samson, Benoit ;

Abbas, Tahir ;

Aucoin, Nathalie ;

Aubin, Francine ;

Koski, Sheryl L. ;

Wei, Alice Chia-chi ;

Magoski, Nadine M. ;

Tu, Dongsheng ;

O'Callaghan, Christopher J. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

[32] Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses [J].

Culine, Stephane ;

Gravis, Gwenaelle ;

Flechon, Aude ;

Soulie, Michel ;

Guy, Laurent ;

Laguerre, Brigitte ;

Mottet, Nicolas ;

Joly, Florence ;

Allory, Yves ;

Harter, Valentin ;

Pfister, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)

[33] Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression [J].

Sheng, Xinan ;

Yang, Kaiwei ;

Ji, Yongpeng ;

Zhou, Li ;

Zou, Benkui ;

Huang, Hang ;

Wang, Yonghua ;

Bai, Xue ;

Feng, Dan ;

Yang, Yong ;

Bian, Jiasheng ;

Yu, Zhixian ;

Niu, Haitao ;

Du, Peng ;

Fang, Jianmin ;

He, Zhisong ;

Guo, Jun .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[34] Phase II study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy in patients with muscle-invasive urothelial cancer (MI-UC): Pathologic and radiologic response, serum tumor markers, and DNA excision repair pathway biomarkers in relation to disease-free survival (DFS) [J].

Qu, Angela Q. ;

Jacobus, Susanna J. ;

Signoretti, Sabina ;

Stack, Edward C. ;

Krajewski, Katherine Maragaret ;

Rosenberg, Jonathan E. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[35] Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses [J].

Pfister, Christian ;

Gravis, Gwenaelle ;

Flechon, Aude ;

Soulie, Michel ;

Guy, Laurent ;

Laguerre, Brigitte ;

Mottet, Nicolas ;

Joly, Florence ;

Allory, Yves ;

Harter, Valentin ;

Culine, Stephane .

EUROPEAN UROLOGY, 2021, 79 (02) :214-221

[36] Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19) [J].

Petrausch, Ulf ;

Spahn, Martin ;

Schneider, Martina ;

Hayoz, Stefanie ;

Rentsch, Cyrill A. ;

Rothschild, Sacha ;

Omlin, Aurelius ;

Cathomas, Richard .

BMJ OPEN, 2023, 13 (06)

[37] Re: Randomized Phase III Trial of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-Invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses [J].

Chang, Sam S. .

JOURNAL OF UROLOGY, 2022, 208 (01) :213-213

[38] SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations [J].

Loriot, Y. ;

Necchi, A. ;

Hussain, S. A. ;

De Velasco Oria, G. A. .

ANNALS OF ONCOLOGY, 2024, 35 :S1163-S1164

← 1 2 3 4 →